Coenfy (xanomeline–trospium), approved by the U.S. Food and Drug Administration in 2024, represents the first antipsychotic with a non-dopaminergic mechanism of action and expands current treatment options by introducing a novel cholinergic therapeutic strategy.
Gabriela Majchrowicz, Mikołaj Jońca, Natasza Kurys et al.· International Journal of Inn...· 0 citations
Alzheimer’s disease (AD) is a chronic, progressive neurodegenerative disorder and the leading cause of dementia worldwide, with prevalence increasing due to population aging. It is characterized by cognitive decline, functional impairment, and significant public health burden. Pathophysiology involves a complex interpl...
Mikołaj Jońca, Gabriela Majchrowicz, Natasza Kurys et al.· International Journal of Inn...· 0 citations
There remains a lack of solid epidemiological evidence demonstrating a rise in the prevalence of ADHD within the general population within the last decade, and currently the data does not support a rise in ADHD prevalence.
Aleksandra Dybcio, Mikhail Kazachok, Szymon Paruszewski et al.· International Journal of Inn...· 0 citations
Background: Autoimmune rheumatic diseases (ARDs) are characterized by a failure of immune tolerance, leading to chronic inflammation, autoantibody production, and progressive organ damage. Conventional therapies often fail to induce long-term, drug-free remission in refractory patients. Chimeric antigen receptor (CAR)...
Mateusz Miluski, D. Szydłowska, Mikołaj Jońca et al.· International Journal of Inn...· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.
